Public recall detail

ZINBRYTA (daclizumab beta) - Voluntary Withdrawal in Canada due to Risk of Encephalitis

medium
Recall Safety notice
Quick summary

Quick summary: ZINBRYTA (daclizumab beta) - Voluntary Withdrawal in Canada due to Risk of Encephalitis .

Recommended action

Recommended action: compare your product with the official notice and follow the instructions published by the official source.

Recall details

Quick summary: ZINBRYTA (daclizumab beta) - Voluntary Withdrawal in Canada due to Risk of Encephalitis .

Official details

Affected product details

Structured information extracted from the official recall notice. Confirm the identifiers and instructions in the original notice.

Brand

Issue

Cases of immune-mediated encephalitis and meningoencephalitis, some with fatal outcomes, have been reported in patients treated with ZINBRYTA. No cases have been reported in Canada.

Additional official information
Background{}
Companies
Audiences

Contains information licensed under the Open Government Licence – Canada. SafetyPulse is independent of the Government of Canada.

Starting...

Related recalls

Similar recalls and safety notices.

Loading related recalls...